Hemostemix Inc

OTC Pink - Current Information:HMTXFUnited StatesView on Canadian Exchange

Oct 31, 2024

Show headlines and story abstract

• Hemostemix Announces the First Tranche Closing of $1.8M of Its Recently Announced Private Placement, from 4:05PM ET on Thursday Oct 31, 2024 by Newsfile

  4:05PM ET on Thursday Oct 31, 2024 by Newsfile
  Companies Mentioned: HMTXF

  Calgary, Alberta--(Newsfile Corp. - October 31, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed its first tranche of the private placement of units ("Units"), as announced on October 11, 2024, for gross proceeds of $1,842,723 (the "Offering"). The Offering consisted of the issuance of an aggregate of 36,854,475 Units at a price of $0.05 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.12 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.

• Hemostemix Announces the First Tranche Closing of $1.8M of Its Recently Announced Private Placement, from 4:05PM ET on Thursday Oct 31, 2024 by Dow Jones

  4:05PM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: HEM
  
  authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.